Form 4: Protara Therapeutics Director Barry P. Flannelly Acquires 10,000 Stock Options

Director Barry P. Flannelly acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.

Summary

• On June 7, 2024, Barry P. Flannelly, a director of Protara Therapeutics, Inc., acquired 10,000 stock options.
• The options have an exercise price of $2.67.
• The options vest in equal monthly installments over 12 months, but will be fully vested by the date of the company's next annual stockholder meeting, subject to continuous service on the board.
• The options will also vest in full upon a Change of Control.
• The expiration date for these options is June 6, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of options by a director could be seen as mildly positive, but it's a routine event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future.

Industry Context

This is a standard disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates